DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Preventive IVIG Therapy for Congenital Heart Block

Information source: New York University School of Medicine
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Congenital Heart Block; Neonatal Lupus; Autoantibody-Associated Heart Block

Intervention: intravenous immune globulin (IVIG) (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: New York University School of Medicine

Official(s) and/or principal investigator(s):
Jill P. Buyon, MD, Principal Investigator, Affiliation: New York University School of Medicine

Overall contact:
Ann R. Rupel, B.A., Phone: 212-263-0745, Email: ann.rupel@nyumc.org

Summary

Neonatal lupus (NL) is the name given to a group of conditions that can affect the babies of mothers who have certain autoantibodies against components of the body’s cells that are called SSA/Ro and SSB/La. NL can appear as a temporary rash that usually goes away by the time the baby is 6 months old, or very rarely an abnormal blood or liver condition that also improves with time – or it can cause permanent and often life-threatening damage to the fetal heart, known as congenital heart block (CHB). In women with anti-Ro/La antibodies who are pregnant for the first time, only about 2% of the babies will develop CHB. But for a woman who has already had a child with CHB or NL rash, the risk of CHB in her next pregnancy is nearly 20%. Unfortunately, once complete (third degree) heart block has been unequivocally identified in a fetus, it has never been reversed with any of the therapies that have been tried to date. Our previous studies strongly indicate that scarring of the conduction system (the heart’s own natural “pacemaker”), a consequence of inflammation triggered by the mother’s antibodies, damages or even destroys the cells that allow the heart to beat at a normal rhythm. Instead, the damaged heart beats extremely slowly, to an extent that is fatal to nearly 20% of affected babies (with most deaths occurring as fetal demises). Nearly all surviving children with CHB require permanent implantation of a pacemaker device. Because it is so difficult to treat or repair the damaged heart, a high-priority strategy is to try to prevent the inflammatory process before irreversible scarring can occur. The aim of this clinical-based proposal is to determine whether treating the pregnant mother with intravenous immune globulin (IVIG) will prevent the development of CHB.

Clinical Details

Official title: Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)

Study design: Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study

Primary outcome: 2nd or 3rd degree heart block

Secondary outcome:

Prolonged PR interval (>0.150 sec)

Sign of myocardial injury, w/o change in heart rate/rhythm

Echocardiographic density consistent with EFE

Fetal death

Rash consistent w neonatal lupus

Gestational age at birth

Birth weight

Abnormal fluid collection

Detailed description: Perhaps the strongest clinical association with autoantibodies against SSA/Ro-SSB/La is the development of congenital heart block (CHB) in an offspring, an alarming prospect facing 2% of primigravid mothers with these antibodies. Recurrence rates approach 20%. Disease can progress rapidly, with advanced block and life-threatening cardiomyopathy observed less than 2 weeks from normal sinus rhythm. Once 3rd degree (complete) block is identified, reversal has never been achieved, despite dexamethasone. This makes biologic sense since the signature lesion is fibrosis of the atrioventricular node. Thus, strategies aimed at preventing disease assume high priority. Although disease expression in the fetus requires additional factors to amplify the cascade to fibrosis, maternal anti-Ro/La antibodies are necessary. Accordingly, eliminating fetal exposure to these antibodies is a sound and important approach. Intravenous immune globulin (IVIG) is particularly exciting in its potential not only to lower maternal antibody levels (which is not accomplished with glucocorticoids or immunosuppression), but actually to influence effector mechanisms in the fetus itself. Aim 1 is a clinical trial to assess the efficacy of IVIG in preventing CHB. Proof of efficacy is challenging since CHB occurs in only 2% of first pregnancies of anti-Ro/La+ women. However, given the 10-fold higher risk of CHB in a pregnancy after the birth of child with neonatal lupus (NL), mothers with previous NL-affected children are the target population for study. Sample size calculations employ Simon’s 2-stage optimal design. Based on a 2-sided significance level of 0. 05, a power of 90% to show reduction of risk to 5% given the prediction that 18% of untreated subjects will get some degree of CHB, Stage 1 will enroll 19 women who have had a previous child with CHB or NL rash, to receive IVIG (400 mg/kg IVIG every 3 weeks for a total of 5 treatments) from weeks 12 through 24 of gestation. If fewer than 3 mothers have children with 2nd or 3rd degree block, then an additional 35 mothers will be enrolled in Stage 2 (total = 54 subjects). IVIG will be considered efficacious and worthy of further study if fewer than 6 of 54 subjects have a child with advanced CHB. Secondary outcomes include 1st degree block, myocardial injury absent conduction defects, and isolated endocardial fibroelastosis as assessed by serial fetal echocardiograms and EKG at birth.

Aim 2 will address: a) the effect of IVIG on antibody titer and subclass; b) genetic polymorphisms in Fc gamma receptor (FcgR) and platelet-activating factor acetylhydrolase and their potential association with response to IVIG; c) whether a decrease in anti-La antibodies positively correlates with the level of anti-La antiidiotypic antibodies; d) whether IVIG blocks expression of activation markers on human macrophages after challenge with opsonized apoptotic cardiocytes and whether this positively correlates with increased expression of the inhibitory Fc receptor, FcgRIIb.

In sum, IVIG is a promising agent that may have effects at several levels of the pathologic cascade to antibody-mediated CHB.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Mother must currently have an intrauterine pregnancy of less than 12 weeks.

- Mother must have antibodies to SSA/Ro and/or SSB/La (will be confirmed in the clinical

immunology laboratory at the Principal Investigator's institution, the NYU-Hospital for Joint Diseases).

- Mother can be asymptomatic or have any rheumatic disease (such as lupus, Sjogren

syndrome or other).

- Mother must have had a previous child with one of the following: (a) congenital heart

block (any degree) documented by EKG if live birth and/or echocardiogram if fetal demise; (b) characteristic neonatal lupus rash confirmed by photograph revealing annular lesions (evaluated by the PI), dermatology note, and/or biopsy; (c) congenital heart block and rash.

- Mother may be taking 20 mg prednisone per day or less.

Exclusion Criteria:

- Mother does not have antibodies to either SSA/Ro or SSB/La.

- Mother is taking greater than 20 mg prednisone per day.

- Mother has any condition that would contraindicate the use of IVIG: (a) prior

serious reaction to IVIG infusion; (b) known IgA deficiency; (c) intolerance of volume load, e. g., congestive heart failure; (d) nephrotic syndrome.

- Identification in the fetus of any of the following structural lesions considered

causal for congenital heart block: (a) atrioventricular septal defects; (b) single ventricle; (c) developmental tricuspid valve disease; (d) L-transposition of the great arteries; (e) heterotaxia.

Locations and Contacts

Ann R. Rupel, B.A., Phone: 212-263-0745, Email: ann.rupel@nyumc.org

Saint Barnabas Medical Center, Livingston, New Jersey 07039, United States; Recruiting
Deborah M. Friedman, MD, Phone: 973-322-5691, Email: dfriedman@sbhcs.com
Deborah M. Friedman, MD, Principal Investigator

New York University School of Medicine / NYU-Hospital for Joint Diseases, New York, New York 10016, United States; Recruiting
Jill P. Buyon, MD, Phone: 212-263-0746, Email: jill.buyon@nyumc.org
Peg Katholi, AA, Phone: 212-263-0743, Email: peg.katholi@nyumc.org
Jill P. Buyon, MD, Principal Investigator
Colin KL Phoon, MD, Sub-Investigator

Additional Information

Starting date: April 2007
Ending date: April 2012
Last updated: April 13, 2007

Page last updated: February 12, 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012